Phase II safety study of bevacizumab in combination with carboplatin and paclitaxel in elderly patients (>70 years) with non-small cell lung cancer [Estudio Fase II de seguridad de bevacizumab en combinacion con carboplatino y paclitaxel en pacientes ancianos (>70 anos) con cancer de pulmon no microcitico]
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Sep 2017 Status changed from recruiting to completed.
- 23 Apr 2013 New trial record